TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a preliminary study, 16 breast cancer survivors who completed eight weeks of oxaloacetate treatment had improved scores on a measure of perceived cognitive impairment. The study had no control group, so it cannot establish that the supplement caused the gains; a placebo-controlled trial is expected to begin enrolling before year-end.
A small study found that breast cancer survivors reported better cognitive function after eight weeks taking oxaloacetate, a supplement involved in cellular energy production. All 16 participants who completed the study improved on the main cognitive assessment, but the trial had no control group and cannot show whether oxaloacetate caused the change; a placebo-controlled study is expected to begin enrolling before year-end.
The participants received 500 milligrams of oxaloacetate twice daily for eight weeks. Researchers enrolled 18 people, and 16 completed the study. The main outcome was perceived cognitive impairment measured using the FACT-Cog PCI assessment. The group’s average score rose from 29.1 at baseline to 55.5 after eight weeks, a level the study described as within the normal range. Improvements were seen by week four and generally increased over the following month.
Researchers also reported improvements in fatigue and physical functioning, along with a trend toward improvement in insomnia. Neuropsychological tests indicated gains in executive function and processing speed. The study report said the treatment was generally well tolerated, with gastrointestinal symptoms among the reported adverse effects, including indigestion, bloating, constipation and diarrhea.
The findings were reported by Patricia Ganz, MD, of UCLA Health in Los Angeles, and colleagues in JCO Oncology Advances. The study focused on survivors who were one to five years past cancer treatment and had moderately severe cognitive impairment on a screening questionnaire. The report describes 16 evaluable participants, but the small sample limits how broadly the results can be applied.
A Possible Option for Persistent Brain Fog
Cancer-related cognitive impairment can affect memory, concentration and other mental functions after treatment, and may interfere with daily activities. The study addresses a problem for which drug-based treatment options are limited. Its results suggest oxaloacetate merits further testing, but they do not establish that it is an effective treatment.
Halle Moore, MD, of Cleveland Clinic, who was not involved in the research, told MedPage Today that the reported changes in patient-perceived cognition, fatigue and physical function were impressive. She also stressed the need for a longer randomized trial with a control group. Such a comparison can help determine whether improvement reflects the supplement, expectations, changes over time or other factors.
The distinction matters to patients considering supplements: the study’s findings are preliminary and do not show that oxaloacetate should replace established cancer care or other support. Its relevance is that researchers have identified a possible approach to test in a more rigorous study, not that benefit has been proven.
oxaloacetate supplement capsules 500 mg
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Oxaloacetate
Cancer-related cognitive impairment is often called “chemo brain” or “brain fog”, although it is not limited to chemotherapy or breast cancer. The condition has been studied extensively in breast cancer survivors, and the source report notes that it also occurs among people treated for other cancers. Its causes and underlying mechanisms remain uncertain.
Oxaloacetate is a naturally occurring human metabolite involved in intracellular energy production and in regulation of glutamate, a neurotransmitter associated with cognitive function. Previous studies have examined oxaloacetate for cognition and fatigue, including a small randomized study in people with long COVID. Those findings provided background for testing it in survivors with diagnosed cognitive impairment; they do not establish that results in one patient group apply to another.
The breast cancer study used an initial design intended to assess whether a larger trial was warranted. After early participants showed a substantial change in perceived cognition, the investigators revised the study to complete it with a smaller sample and move toward a randomized trial. That change, together with the absence of a control group, is important when interpreting the results.
“These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment.”
— Patricia Ganz, MD, UCLA Health, in a press release
FACT-Cog cognitive function assessment workbook
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Small Trial Cannot Show
Because the study was single-arm and had no placebo group, it cannot determine how much of the score change was due to oxaloacetate. The results may also be affected by expectations, repeated testing, natural changes in symptoms or other influences. The small number of participants means the findings may not represent the broader population of cancer survivors.
The study report does not establish how long any improvement lasts after treatment ends, whether the supplement benefits people with cancers other than breast cancer, or which patients might respond. The available source also does not provide detailed rates for each adverse effect or enough information to assess uncommon or longer-term risks. The reported cognitive gains are measures from a preliminary study, not confirmation of a lasting clinical benefit.
brain fog journal for memory and concentration tracking
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
A Placebo-Controlled Trial Ahead
A phase II randomized, placebo-controlled study is expected to begin enrollment before the end of 2026, according to the report. Comparing oxaloacetate with a placebo should provide a clearer test of whether the improvement seen in the preliminary study exceeds changes that might occur without the supplement.
Details such as the planned enrollment, trial locations, follow-up period and outcome measures were not provided in the source material. Until results from a controlled study are available, the effect and safety of oxaloacetate for cancer-related cognitive impairment remain under investigation.
cancer survivorship fatigue and cognitive support workbook
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is oxaloacetate?
Oxaloacetate is a naturally occurring metabolite involved in cellular energy production and regulation of the neurotransmitter glutamate. This study tested it as a supplement in breast cancer survivors with cognitive impairment.
Did the study prove that oxaloacetate treats brain fog?
No. The study found improved cognitive assessment scores among participants who completed treatment, but it had no placebo or control group. A randomized trial is needed to better test whether oxaloacetate caused the improvement.
How many people took part?
The researchers enrolled 18 participants; 16 completed the eight-week study and were included among the evaluable patients. The small sample limits how widely the results can be applied.
What side effects were reported?
The report describes the treatment as generally well tolerated and lists gastrointestinal symptoms, including indigestion, bloating, constipation and diarrhea. The preliminary study does not establish the supplement’s longer-term safety.
When will oxaloacetate be tested further?
A phase II placebo-controlled trial is expected to begin enrolling before the end of 2026, according to the report. Further study details and results were not available in the source material.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
